Reported Saturday, Nektar's Rezpegaldesleukin Shows Statistically Significant EASI Improvements In 393-Patient Phase 2b REZOLVE-AD Trial And Proof-Of-Concept In Alopecia Areata At AAD 2026

Nektar Therapeutics (Nasdaq: NKTR) reported statistically significant improvements in the mean percent EASI scores for patients with moderate and severe atopic dermatitis in its Phase 2b REZOLVE-AD trial involving 393 patients. Additionally, the company presented proof-of-concept data for Rezpegaldesleukin in alopecia areata during a late-breaking research oral presentation at the 2026 American Academy of Dermatology Annual Meeting in Denver, CO.